ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

27.45

+0.19 (0.70%)

Oct 7, 2024, 4:00 PM EDT - Market closed

0.70% (1D)

Market Cap	921.93M
Revenue (ttm)	n/a
Net Income (ttm)	-74.89M
Shares Out	33.59M
EPS (ttm)	-4.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	194,999
Open	27.16
Previous Close	27.26
Day's Range	27.09 - 28.17
52-Week Range	14.35 - 30.99
Beta	n/a
Analysts	Strong Buy
Price Target	36.80 (+34.06%)
Earnings Date	Nov 2, 2024

About AVBP

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal grow... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 26, 2024

Employees 40

Stock Exchange NASDAQ

Ticker Symbol AVBP

Website https://www.arrivent.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price forecast is $36.8, which is an increase of 34.06% from the latest price.

Price Target

$36.8

(34.06% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median durat...

4 weeks ago - GlobeNewsWire

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics is pleased to announce that ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program.

7 weeks ago - Business Wire

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at t...

7 weeks ago - GlobeNewsWire

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session

2 months ago - GlobeNewsWire

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Collaboration will leverage Alphamab's antibody drug conjugate (“ADC”) research and discovery platform and ArriVent's global development and commercialization expertise

4 months ago - GlobeNewsWire

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, t...

5 months ago - GlobeNewsWire

ArriVent BioPharma Reports First Quarter 2024 Financial Results

NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of in...

5 months ago - GlobeNewsWire

ArriVent Appoints Kristine Peterson to its Board of Directors

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,...

6 months ago - GlobeNewsWire

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

BEIJING, China--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study...

6 months ago - Business Wire